4-(2-氧代-乙基)-哌嗪-1-羧酸叔丁酯 | 945953-41-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 4-(2-氧代-乙基)-哌嗪-1-羧酸叔丁酯
• 英文名称: tert-butyl 4-(2-oxoethyl)piperazine-1-carboxylate
• CAS: 945953-41-3
• 化学式: C₁₁H₂₀N₂O₃
• mdl: MFCD09832218
• 分子量: 228.291
• InChiKey: KGXKHDJWDRHJSH-UHFFFAOYSA-N

物化性质

• 沸点：
  303.9±37.0 °C(Predicted)
• 密度：
  1.083±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.818
• 拓扑面积：
  49.8
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2933599090
• 危险性防范说明：
  P261,P264,P270,P271,P280,P302+P352,P304+P340,P305+P351+P338,P312,P330,P362,P403+P233,P501
• 危险性描述：
  H302,H312,H332

反应信息

• 作为反应物：
  描述：

  4-(2-氧代-乙基)-哌嗪-1-羧酸叔丁酯 在 palladium on activated charcoal 六甲基磷酰三胺 、 氢气 、 三氟乙酸 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 14.0h， 生成 1-[β-(4-oxo-4,5,6,7-tetrahydrobenzofuran-5-yl)ethyl]piperazine
  参考文献：
  名称：

  Multistructure 3D-QSAR Studies on a Series of Conformationally Constrained Butyrophenones Docked into a New Homology Model of the 5-HT_2A Receptor

  摘要：

  The present study is part of a long-term research project aiming to gain insight into the mechanism of action of atypical antipsychotics. Here we describe a 3D-QSAR study carried out on a series of butyrophenones with affinity for the serotonin-2A receptor, aligned by docking into the binding site of a receptor model. The series studied has two peculiarities: (i) all the compounds have a chiral center and can be represented by two enantiomeric structures, and (ii) many of the structures can bind the receptor in two alternative orientations, posing the problem of how to select a single representative structure for every compound. We have used an original solution consisting of the simultaneous use of multiple structures, representing different configurations, binding conformations, and positions. The final model showed good statistical quality (n = 426, r(2) = 0.84, q(LOO)(2) = 0.81) and its interpretation provided useful information, not obtainable from the simple inspection of the ligand-receptor complexes.

  DOI：

  10.1021/jm070277a
• 作为产物：
  描述：

  1-Boc-4-乙氧基羰基甲基哌嗪 在 lithium aluminium tetrahydride 、 草酰氯 、 二甲基亚砜 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 28.0h， 生成 4-(2-氧代-乙基)-哌嗪-1-羧酸叔丁酯
  参考文献：
  名称：

  신규 오토탁신 저해 화합물 및 이를 함유하는 약제학적 조성물

  摘要：

  本发明涉及用于治疗或预防由自噬活化或增加的氧化磷酸化酸浓度引起的病症或疾病的新自噬抑制剂及其含有药剂学组合物。本发明的新化合物作为自噬抑制剂，通过抑制氧化磷酸化酸的生成，对心血管疾病、癌症、代谢性疾病、肾脏疾病、肝脏疾病、炎症性疾病、神经系统疾病、呼吸系统疾病、纤维性疾病、眼科疾病、糖尿病性视网膜病变及其他形式的慢性肾病或急性或慢性器官移植排斥反应的治疗或预防有益。

  公开号：

  KR101798840B1

文献信息

• Structure–Activity Relationship of Sulfonyl Piperazine LpxH Inhibitors Analyzed by an LpxE-Coupled Malachite Green Assay
  作者：Minhee Lee、Jinshi Zhao、Seung-Hwa Kwak、Jae Cho、Myungju Lee、Robert A. Gillespie、Do-Yeon Kwon、Hyunji Lee、Hyun-Ju Park、Qinglin Wu、Pei Zhou、Jiyong Hong

  DOI：10.1021/acsinfecdis.8b00364

  日期：2019.4.12

  quantified by the colorimetric malachite green assay, allowing the monitoring of the LpxH catalysis. Using such a coupled enzymatic assay, we report the biochemical characterization of a series of sulfonyl piperazine LpxH inhibitors. Our analysis establishes a preliminary structure-activity relationship for this class of compounds and reveals a pharmacophore of two aromatic rings, two hydrophobic groups,

  脂质A生物合成的Raetz途径中的UDP-2,3-二酰基葡萄糖胺焦磷酸酶LpxH是绝大多数革兰氏阴性病原体中的必需酶，并且是出色的新型抗生素靶标。32P放射自显影薄层色谱分析法已广泛用于分析LpxH活性，但在较长时间内无法评估大量LpxH抑制剂。在这里，我们报告了一种耦合的非放射性LpxH分析方法，该方法利用最近发现的Aquifex aeolicus脂质A 1-磷酸酶LpxE从脂质X（LpxH催化产物）中定量去除1-磷酸。随后通过比色孔雀石绿测定法对释放的无机磷酸盐进行定量，从而可以监测LpxH催化作用。使用这种耦合酶法，我们报告了一系列磺酰基哌嗪LpxH抑制剂的生化特性。我们的分析建立了这类化合物的初步结构-活性关系，并揭示了两个芳环，两个疏水基团和一个氢键受体的药效基团。我们希望我们的发现将有助于开发更有效的LpxH抑制剂作为潜在的抗菌剂。
• COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR
  申请人：Arvinas, Inc.

  公开号：US20180099940A1

  公开（公告）日：2018-04-12

  The present disclosure relates to bifunctional compounds, which find utility to degrade and (inhibit) Androgen Receptor. In particular, the present disclosure is directed to compounds, which contain on one end a cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds Androgen Receptor, such that Androgen Receptor is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of Androgen Receptor. The present disclosure exhibits a broad range of pharmacological activities associated with compounds according to the present disclosure, consistent with the degradation/inhibition of Androgen Receptor.

  本公开涉及双功能化合物，其用于降解和（抑制）雄激素受体。具体而言，本公开涉及包含一端结合到E3泛素连接酶的谷氨酰腺苷环配体，另一端结合到雄激素受体的部分的化合物，使得雄激素受体与泛素连接酶靠近，以实现雄激素受体的降解（和抑制）。本公开展示了与根据本公开涉及的化合物相关的广泛的药理活性范围，与雄激素受体的降解/抑制一致。
• [EN] ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER<br/>[FR] CONJUGUÉ ANTICORPS-MÉDICAMENT ET SON UTILISATION POUR LE TRAITEMENT DU CANCER
  申请人：PF MEDICAMENT

  公开号：WO2015162293A1

  公开（公告）日：2015-10-29

  The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to a Target, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.

  本发明涉及一种抗体药物偶联物。从一方面来说，该发明涉及一种抗体药物偶联物，包括一种能够与靶标结合的抗体，所述抗体与至少一种选自多拉司汀10衍生物和奥里司汀衍生物的药物偶联。该发明还包括治疗方法以及使用所述抗体药物偶联物治疗癌症的应用。
• [EN] LPXH TARGETING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF MAKING AND USING THE SAME<br/>[FR] COMPOSÉS DE CIBLAGE LPXH, LEURS COMPOSITIONS ET PROCÉDÉS DE FABRICATION ET D'UTILISATION ASSOCIÉS
  申请人：UNIV DUKE

  公开号：WO2021072369A1

  公开（公告）日：2021-04-15

  LpxH targeting compounds, compositions thereof, as well as methods for for making and using the same are disclosed herein. The LpxH target compounds typically have a structure pursuant to Formula (I) and/or a salt thereof, wherein Rb is selected from a single bond, C4 to C10 unsubstituted aryl, C4 to C10 substituted aryl, unsubstituted or substituted four to ten member heterocycle ring, C1 to C10 unsubstituted alkyl, and C1 to C10 substituted alkyl; Rc comprises hydrogen, halogen, -OH, -CO2CH3, -COOH, -CN2CF3, -CF3,-C2OH, -CONHOH, -CCOH, C4 to C10 unsubstituted aryl, C4 to C10 substituted aryl, unsubstituted or substituted four to ten member heterocycle ring, C1 to C10 unsubstituted alkyl, or C1 to C10 substituted alkyl; and Rd and Re are independently hydrogen, -OH, -COH, -COH, -COC, -COOH, Rf, or are taken together as an unsubstituted or substituted four to eight member nitrogen containing heterocycle ring.

  LpxH靶向化合物，其组合物，以及制备和使用这些化合物的方法在此披露。LpxH靶向化合物通常具有符合式(I)的结构和/或其盐，其中Rb从单键，C4到C10未取代芳基，C4到C10取代芳基，未取代或取代的四到十元杂环环，C1到C10未取代烷基，和C1到C10取代烷基中选择；Rc包括氢，卤素，-OH，-CO2CH3，-COOH，-CN2CF3，-CF3，-C2OH，-CONHOH，-CCOH，C4到C10未取代芳基，C4到C10取代芳基，未取代或取代的四到十元杂环环，C1到C10未取代烷基，或C1到C10取代烷基；而Rd和Re独立地是氢，-OH，-COH，-COH，-COC，-COOH，Rf，或作为未取代或取代的四到八元含氮杂环环一起取代。
• [EN] BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE<br/>[FR] AGENTS DE DÉGRADATION BIFONCTIONNELS ET LEURS MÉTHODES D'UTILISATION
  申请人：NOVARTIS AG

  公开号：WO2021053495A1

  公开（公告）日：2021-03-25

  Described herein are bifunctional degrader compounds, their various targets, their preparation, pharmaceutical compositions comprising them, and their use in the treatment of conditions, diseases, and disorders mediated by various target proteins.

  本发明描述了双功能降解剂化合物、它们的多种靶点、它们的制备方法、包含它们的药物组合物，以及它们在治疗由各种靶点蛋白质介导的条件、疾病和失调症中的用途。